Definitions of VAP and Related Terminologies
Ventilator-associated pneumonia (VAP) is defined as pneumonia occurring more than 48 hours after endotracheal intubation, while hospital-acquired pneumonia (HAP) is pneumonia developing ≥48 hours after hospital admission in non-ventilated patients. 1
Core Definitions
Hospital-Acquired Pneumonia (HAP)
HAP represents infection of the pulmonary parenchyma by hospital pathogens, developing ≥48 hours after hospital admission and not incubating at the time of admission. The diagnosis requires new lung infiltrate plus clinical evidence of infection (new fever, purulent sputum, leukocytosis, declining oxygenation). Critically, HAP and VAP are mutually exclusive categories - HAP specifically excludes ventilator-associated cases to avoid confusion. 1, 2
Ventilator-Associated Pneumonia (VAP)
VAP develops in ICU patients who have been mechanically ventilated for at least 48 hours. Patients requiring mechanical ventilation after pneumonia onset do not meet VAP criteria - the ventilation must precede the infection. 2 The incidence ranges from 2-16 episodes per 1000 ventilator-days, with risk highest early (3% per day during first 5 days, decreasing to 1% per day thereafter). 2
Early-Onset vs Late-Onset VAP
While the guidelines acknowledge this distinction exists in clinical practice and literature 3, the 2016 IDSA/ATS guidelines notably do not provide specific time cutoffs or differential management recommendations based on early versus late onset, representing a shift from older paradigms. Research typically defines early-onset as occurring within 4-5 days of intubation, associated with community pathogens, while late-onset (>5 days) correlates with multidrug-resistant (MDR) organisms. 3, 4
Ventilator-Associated Tracheobronchitis (VAT)
VAT is characterized by signs of respiratory infection (fever, purulent secretions, positive cultures) without new radiographic infiltrates in patients ventilated ≥48 hours. This distinguishes it from VAP, where parenchymal infiltrates are required. 2
Related Terminology
Healthcare-Associated Pneumonia (HCAP)
The 2016 IDSA/ATS guidelines explicitly rejected HCAP as a useful category, determining it should not be included in HAP/VAP guidelines. 1 The European guidelines define HCAP as pneumonia in non-hospitalized patients with multiple risk factors for MDR colonization (hospitalization ≥2 days within 90 days, nursing home residence, recent antibiotics, hemodialysis, wound care). 2 However, the panel recognized that MDR risk should be based on validated risk factors, not simply healthcare contacts.
ICU-Acquired Pneumonia
This term refers to pneumonia developing in ICU patients, encompassing both HAP occurring in the ICU and VAP. Approximately one-third of nosocomial pneumonias are ICU-acquired. 2
Multidrug-Resistant (MDR) Pathogens
While not explicitly defined in the provided guidelines, MDR pathogens represent organisms resistant to multiple antibiotic classes. Risk factors include prolonged mechanical ventilation, prior antibiotic treatment, and healthcare system contact. 5 Common MDR organisms in VAP include Acinetobacter baumannii, Pseudomonas aeruginosa, and carbapenem-resistant Klebsiella pneumoniae. 4, 6
Colonization vs Infection
This distinction is critical but not explicitly defined in the guidelines provided. Colonization represents bacterial presence without host inflammatory response or tissue invasion, while infection involves active disease with clinical manifestations. Respiratory tract colonization in ICU patients is complex, involving both self-colonization and cross-transmission. 5
Prevention-Related Terms
Subglottic Secretion Drainage
This refers to continuous or intermittent aspiration of secretions that pool above the endotracheal tube cuff, preventing their descent into the lower airways. Special endotracheal tubes with dedicated suction ports enable this intervention, which has been shown to reduce VAP incidence (8.3% vs 21.7% in matched cohorts). 7, 8
Endotracheal Cuff Pressure Control
Maintaining adequate cuff pressure (typically 20-30 cm H₂O) prevents microaspiration of contaminated oropharyngeal secretions around the cuff into the lower respiratory tract. 8
Selective Digestive Decontamination (SDD)
While mentioned in the context of prevention, specific definitions are not provided in the guidelines. SDD typically involves topical antimicrobial application to the oropharynx and gastrointestinal tract to reduce colonization by pathogenic organisms.
Aspiration
The guidelines reference aspiration as a key mechanism in VAP pathogenesis, particularly in trauma and brain injury patients with depressed consciousness (50% VAP incidence). 2 Microaspiration of contaminated secretions represents the primary route of bacterial entry into the lower respiratory tract.
Important Caveats
The guidelines explicitly reject CDC ventilator-associated events (VAE) definitions for clinical diagnosis and treatment decisions - these surveillance metrics are designed for population-level quality monitoring, not bedside care. 1 There is no gold standard for VAP diagnosis, and definitions vary across studies, complicating the literature. 1, 9
The mortality attributable specifically to VAP remains debated, though overall mortality ranges from 20-70% depending on pathogens and appropriateness of initial therapy. 5 VAP consistently prolongs mechanical ventilation duration, ICU stay, and hospitalization, with mean attributable costs of approximately $10,000-40,000 per episode. 2